Jun42020 Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease June 4, 2020
Apr232020 Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease April 23, 2020
Mar312020 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 March 31, 2020
Dec162019 Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates December 16, 2019
Dec102019 Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 December 10, 2019
Dec42019 Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference December 4, 2019
Oct92019 Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Jul172019 Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association International Conference (AAIC) July 17, 2019
Oct262018 Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting October 26, 2018
Sep262018 Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference September 26, 2018
Aug282018 First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease August 28, 2018
